Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SCNIBullishCorporate Developmentsnews

High materiality8/10

Scinai Immunotherapeutics Secures $2.61 Million Financing for CDMO Expansion

Apr 24, 2026, 8:03 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The capital obtained through the financing is likely to facilitate key growth initiatives for SCNI, historically leading to positive market reactions for similar biotech funding events that show strong institutional interest.

AI summary

What happened, with direct paths to the underlying reporting

Scinai Immunotherapeutics Ltd. has secured $2.61 million in funding via a private placement. This capital will support the expansion of their Contract Development and Manufacturing Organization (CDMO) and facilitate growth in customer programs, impacting future operations and market positioning.

SCNI raised $2.61 million through private placement financing.
5.2 million ADSs sold at $0.48 each, plus warrants.
Proceeds will support CDMO expansion and customer programs.
Expected closing of transactions by April 27, 2026.
Institutional life sciences investor led the financing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.